focus -WSS

focus

author：leisure time 2025-08-27 16:48:05 - browse：5

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA advisory panel to debate high blood pressure devices

WSS

As obesity drug market grows, telehealth companies court payers

FDA advisers back CAR

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Why depression after traumatic brain injury is distinct

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Hospital at home shows how to bring innovation to health care

hotspot

focus

focus

23andMe had bad news about my health. I wish a person had delivered it

People can get long Covid without testing positive for virus: Study

Drug repurposing or repositioning? The language matters

Why scientists need input from humanists on sensitive research

What does generative AI mean for health care? We asked experts

Health officials lay out plans to cope with respiratory virus season

Medicare proposal to cover medical devices draws a mixed reaction

Health officials lay out plans to cope with respiratory virus season

Duchenne breakthrough therapy leaves behind pioneering families

Meadows told special counsel he could not recall Trump ever declassifying Mar

focus

PBMs are inflating the cost of generic drugs. They must be reined in

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How the first Native Hawaiian psychiatrist helped diversify medicine

How many hemophilia patients actually want gene therapy?

FDA advisory panel to debate high blood pressure devices

FDA greenlights medical device to combat bladder issues

knowledge

explore

knowledge

Wikipedia